Clinical Trials Logo

Heroin Dependence clinical trials

View clinical trials related to Heroin Dependence.

Filter by:

NCT ID: NCT00142948 Completed - Heroin Dependence Clinical Trials

Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts

Start date: February 2006
Phase: Phase 2
Study type: Interventional

Naltrexone is a medication that is currently used to treat drug and alcohol addiction. Guanfacine is a medication that is currently used to manage the withdrawal symptoms in individuals undergoing opioid detoxification. A combination of these two medications may be beneficial in reducing heroin use in individuals addicted to heroin. This study will evaluate the effectiveness of naltrexone and guanfacine, alone and in combination, at reducing heroin use in heroin addicts.

NCT ID: NCT00135759 Completed - Clinical trials for Substance-Related Disorders

Addition of Naltrexone to Methadone Taper

Start date: April 2005
Phase: Phase 2
Study type: Interventional

There is a continuing search for more effective opiate detoxification treatments. This study's purpose is to investigate the effects of adding very low doses of naltrexone to a methadone tapering treatment in opioid dependent individuals.

NCT ID: NCT00032968 Completed - Heroin Dependence Clinical Trials

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

Start date: January 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.

NCT ID: NCT00032955 Completed - Heroin Dependence Clinical Trials

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

Start date: February 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess buprenorphine/naloxone versus clonidine for inpatient opiate detoxification.

NCT ID: NCT00023283 Completed - Clinical trials for Opioid-Related Disorders

Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1

Start date: August 2000
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the Standard Medical Management (SMM) vs. SMM enhanced with additional education about addiction and recovery (Enhanced Medical Management, EMM)

NCT ID: NCT00015340 Completed - Clinical trials for Substance-Related Disorders

Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14

Start date: August 1999
Phase: Phase 4
Study type: Interventional

The purpose of this study is the safety and efficacy of Buprenorphine/Naloxone in the treatment of opioid dependence. A compassionate use study.

NCT ID: NCT00015288 Completed - Clinical trials for Opioid-Related Disorders

Buprenorphine and Naloxone Combination Study - 10

Start date: November 1996
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine pharmacokinetics and dose proportionality of sublingual tablets containing varying doses of buprenorphine and naloxone.

NCT ID: NCT00015171 Completed - Clinical trials for Substance-Related Disorders

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1

Start date: April 1996
Phase: Phase 3
Study type: Interventional

The purpose of this study is the use of buprenorphine/naloxone in treatment of opioid dependence.

NCT ID: NCT00000331 Withdrawn - Clinical trials for Opioid-Related Disorders

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6

Start date: December 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.

NCT ID: NCT00000330 Withdrawn - Clinical trials for Opioid-Related Disorders

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

Start date: October 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the abuse liability and reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in heroin-dependent volunteers